Patient Centric Research
… modalities for NASH. This data, combined with the TARGET- NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease.” Boehringer Ingelheim has a broad patient centric research and development program in metabolic diseases, encompassing diabetes as well as its contributing factors and complications. NASH is one of the company’s key focus diseases in this therapy area with a high unmet …
Patient Centricity
WEST PALM BEACH, Fla. Integra Connect , the leading provider of technologies and services for value-based specialty care, today announced it has been selected by the Quality Cancer Care Alliance Network (QCCA), the first clinically integrated nationwide network of community oncology practices, as its preferred partner for population health analytics technology and to provide support for value-based care payment models. As a QCCA preferred partner, Integra Connect will offer …
Gateway for Cancer Research Announces Recipient of 4th Annual Young Investigators Award Share Article Gateway for Cancer Research (Gateway), a non-profit dedicated to funding transformational cancer research, and the Conquer Cancer Foundation of the American Society of Clinical Oncologists (ASCO) have announced the recipient of the 2019 Young Investigators Award. The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology …
Real World Evidence
WEST PALM BEACH, Fla. Integra Connect , the leading provider of technologies and services for value-based specialty care, today announced it has been selected by the Quality Cancer Care Alliance Network (QCCA), the first clinically integrated nationwide network of community oncology practices, as its preferred partner for population health analytics technology and to provide support for value-based care payment models. As a QCCA preferred partner, Integra Connect will offer …
… outcomes, will enable our collaborators to continue to increase their understanding of this growing disease.” Boehringer Ingelheim has a broad patient centric research and development program in metabolic diseases, encompassing diabetes as well as its … and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. TARGET PharmaSolutions was formed in February, 2015 and …
About:
Editor:
